All In Biotech

NDA 019574 · Casper Pharma LLC

Thalitone

Chlorthalidone · Oral · Thiazide-like Diuretic

Last checked: Nov 19, 2026Latest source record: Sep 17, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Dec 20, 1988

Approved uses

1

Original approval plus efficacy supplements

Registered trials

92

39 Phase 3, 5 recruiting

FAERS reports

11,770

7,408 serious, 704 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 25, 2026.

THALITONE is a thiazide-like diuretic indicated: • For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). • as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome (1.2). 1.1 Hypertension THALITONE ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with THALITONE. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely...

Mechanism: Chlorthalidone is a long-acting oral diuretic with antihypertensive activity. The diuretic effects of chlorthalidone and the benzothiadiazine (thiazide) diuretics appear to arise from similar mechanisms and the maximal effect of chlorthalidone and the thiazides appear to be similar. The site of the action appears to be the distal convoluted tubule of the nephron. Although the mechanism of action of chlorthalidone and related drugs is not wholly clear, sodium and water depletion appear to provide a basis for its antihypertensive effect.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 20, 1988 Original approval · Type 3 - New Dosage Form
2 products under this application
  • THALITONE · CHLORTHALIDONE 15MG · TABLET, ORAL · Prescription
  • THALITONE · CHLORTHALIDONE 25MG · TABLET, ORAL · Discontinued · TE BX

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorthalidone" as an intervention, any sponsor and status, largest first.

All 92 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue919
  • nausea758
  • drug ineffective756
  • diarrhoea700
  • dizziness598
  • pain569
  • off label use564
  • headache557
  • dyspnoea536
  • acute kidney injury476
  • chronic kidney disease461
  • arthralgia457

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200432
200540
200661
200744
200868
200988
2010128
2011171
2012215
2013224
2014344
2015535
2016671
2017615
2018785
2019953
2020887
2021954
20221,064
20231,009
20241,056
20251,135
2026691

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Thalitone (Chlorthalidone)

2024 spending

$578K

Beneficiaries

1,493

3,517 claims

Per beneficiary

$387

$3.56 per unit

View as table
YearSpending
2020$0
2021$12,930
2022$312,224
2023$538,436
2024$578,075

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 505 on PubMed

Sponsor: Casper Pharma LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.